Preclinical data in murine GBM models has revealed improved survival in LAG3 knockout mice receiving anti-PD1 treatment compared to wild-type (WT) mice treated with anti-PD1, suggesting that LAG3 inhibition may potentiate the anti-tumoral effect of anti-PD1 (Harris-Bookman et al., 2018). Here, LAG3 is linked to glioblastoma.